Clinical trials: Plateau Phase Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002653
- Testing
- carmustine, cyclophosphamide, doxorubicin hydrochloride
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Medical Research Council
Relapsed Multiple Myeloma, Plateau Phase Multiple Myeloma
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
The purpose of the study is to determine the safety and effectiveness of providing 2-methoxyestradiol to patients with plateau phase or relapsed multiple myeloma. Information regarding trough 2ME2 levels will also be collected.
- Trial name
- NCT00592579
- Testing
- 2-methoxyestradiol
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- CASI pharmaceuticals, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Biological therapies, such as interferon-gamma and aldesleukin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00616720
- Testing
- aldesleukin, idiotype-pulsed autologous dendritic cell vaccine APC8020, recombinant interferon gamma
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Relapsed, Refractory or Plateau Phase Multiple Myeloma
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
To evaluate the response rate (Complete Response [CR] and Partial Response [PR]) to dasatinib in patients with relapsed, refractory or plateau phase multiple myeloma whose serum paraprotein levels are >0.5g/dL or urine…
- Trial name
- NCT00429949
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Relapsed or Plateau-Phase Multiple Myeloma
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.
- Trial name
- NCT00259740
- Testing
- DENOSUMAB
- Volunteers
- 96 people
- Sponsor
- Amgen
Multiple Myeloma de Novo Treatment
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.
The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line treatment of multiple myeloma as induction treatment in young patients, with Dexamethasone before autotransplant, and in elderly patients…
- Trial name
- MAG 2002 (NCT01070862)
- Testing
- Thalidomide, Dexamethasone, Vincristin , Adriamycin, Dexamethasone = VAD, Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)
- Where
- 3 sites in France
- Sponsor
- University Hospital, Caen
Multiple Myeloma
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination. The primary purpose of this study is to ascertain whether vaccination with tecemotide (L-BLP25) induces a…
- Trial name
- NCT01094548
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Myeloma and Plasma Cell Neoplasm
Interleukin-12 in Treating Patients With Multiple Myeloma
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's blood cells to kill multiple myeloma cells.
- Trial name
- NCT00003149
- Testing
- recombinant interleukin-12
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eastern Cooperative Oncology Group